MINeralocorticoid Dysregulation in Chronic Kidney Disease

HS Greater Glasgow and Clyde (UK)0 个研究点目标入组 48 人开始时间: 2014年1月10日最近更新: 2020年7月6日

试验速览

暂无简介。

•1. Individuals aged between 18 and 80 years
•2. Individuals with capacity
•3. Renal group:
•3.1 Patients with CKD who attend the Western Infirmary renal unit and its satellite units CKD stage 3 and CKD stage 4 [decline in glomerular filtration rate (GFR) <5ml/min in preceding 6 months]
•3.2 Proteinuric [polymerase chain reaction (PCR) =100mg/mmol] and non proteinuric (PCR <50mg/mmol) patients will be included
•3.3 Patients' blood pressure (BP) should be controlled <160/90 mmHg (where applicable patients should be on a stable dose of antihypertensive for four weeks prior to consent for study)
•4. Hypertensive group:
•4.1 Patients who attend the hypertension clinic at Western Infirmary Glasgow (WIG) or Glasgow Royal Infirmary (GRI)
•4.2 Patients' BP should be controlled <160/90 mmHg (where applicable patients should be on a stable dose of antihypertensive for four weeks prior to consent for study)
•4.3 No significant proteinuria (PCR <20 mg/mmol)

•1. Individuals unable to give informed consent
•2. Diabetes mellitus (possibility of type 4 renal tubular acidosis ? hyporeninaemic hypoaldosteronism)
•3. Patients with nephrotic range proteinuria (PCR =300 mg/mmol)
•4. Patients on aldosterone antagonist or direct renin inhibitor
•5. Individuals pregnant or breast feeding
•6. Patients with a history of Conn?s syndrome, Cushing?s disease or Addison?s disease
•7. Patients who require maintenance corticosteroids or patients who have had corticosteroid treatment within 3 months prior to study commencing
•8. Renal group - patients with progressive (decline in eGFR of >5 ml/min) renal disease in the six months leading up to study start date

发起方

HS Greater Glasgow and Clyde (UK)